By vgreene, 5 September, 2017 At end of tx: Re-educate parent/guardian about s/sx of TB dz, provide tx documentation14
By vgreene, 5 September, 2017 If pt experiences possible AE, advise stopping meds immediately and contacting HCP; do not wait until next clinic visit
By vgreene, 5 September, 2017 Clinical monitoring: Arrange for monthly pt visit; assess for compliance, s/sx of TB dz, and/or adverse effects, esp hepatitis (jaundice, loss of appetite, fatigue, and/or muscle/joint aches)
By vgreene, 5 September, 2017 Address barriers10-12 to pt adherence; recognize and address episodes of nonadherence ASAP. Adopt techniques for improvement13
By vgreene, 5 September, 2017 Baseline/periodic lab testing not routine, unless high-risk pt or if sx of hepatitis develop on tx9
By vgreene, 5 September, 2017 Use DOT in pts on intermittent dosing regimen, incl pts at esp high risk for TB dz who are suspected of nonadherence
By vgreene, 5 September, 2017 Choose LTBI tx regimen based on drug susceptibility results of presumed source case (if known), coexisting medical illness, and potential for drug-drug interactions
By vgreene, 5 September, 2017 Choose LTBI tx regimen based on drug susceptibility results of presumed source case (if known), coexisting medical illness, and potential for drug-drug interactions
By vgreene, 5 September, 2017 Choose LTBI tx regimen based on drug susceptibility results of presumed source case (if known), coexisting medical illness, and potential for drug-drug interactions
